Kezar Life Sciences, Inc.
KZRDelisted May 11, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645666
Kezar Life Sciences, Inc. was delisted on May 11, 2026; its insiders filed their last Form 4 on May 11, 2026; 43 institutions reported holding it in 13F filings for Q1 2026, worth $32.8M in total; no superinvestor held it.
Q3 2024 vs. Q2 2024
How the institutions holding Kezar Life Sciences, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 81 | 1 | 60 | −20 |
| Shares | 39.4M | 830.4K | 39.1M | +544.7K (+1.4%) |
| Value | $23.6M | $498.2K | $31.6M | +$8.52M (+36.8%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (5)
Institutions that held Kezar Life Sciences, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Tang Capital Management LLC | 3,640,300 | $2.81M | 0.20% |
| BlackRock, Inc. | 828,578 | $640.7K | 0.00% |
| Valence8 US LP | 21,136 | $16.3K | 0.01% |
| Ground Swell Capital, LLC | 10,800 | $8.35K | 0.01% |
| Engineers Gate Manager LP | 10,564 | $8.17K | 0.00% |
Sold out (25)
Institutions that held Kezar Life Sciences, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BNP Paribas Arbitrage, SA | 443,724 | $266.2K |
| Schroder Investment Management Group | 350,394 | $210.2K |
| D. E. Shaw & Co., Inc. | 246,841 | $148.1K |
| Y-Intercept (Hong Kong) Ltd | 227,701 | $136.6K |
| Centiva Capital, LP | 147,800 | $88.7K |
| Mackenzie Financial Corp | 58,709 | $35.2K |
| Prosight Management, LP | 56,080 | $33.6K |
| Paloma Partners Management Co | 56,059 | $33.6K |
| Schonfeld Strategic Advisors LLC | 44,400 | $26.6K |
| Mirae Asset Global ETFs Holdings Ltd. | 35,794 | $21.5K |
| Virtu Financial LLC | 35,657 | $21.0K |
| Rhumbline Advisers | 27,551 | $16.5K |
| Jump Financial, LLC | 22,625 | $13.6K |
| Prelude Capital Management, LLC | 18,550 | $11.1K |
| JustInvest LLC | 12,608 | $7.57K |
| Occudo Quantitative Strategies LP | 12,147 | $7.29K |
| Verition Fund Management LLC | 11,898 | $7.14K |
| Point72 (DIFC) Ltd | 11,669 | $7.00K |
| Two Sigma Securities, LLC | 11,212 | $6.73K |
| Russell Investments Group, Ltd. | 6,434 | $3.86K |
| Macquarie Group Ltd | 3,627 | $2.18K |
| Royal Bank of Canada | 3,461 | $2.00K |
| New York State Common Retirement Fund | 605 | $363 |
| CWM, LLC | 79 | $0 |
| Capital Advisors, Ltd. LLC | 719 | $0 |
Not filed for Q3 2024 yet (1)
Institutions that held Kezar Life Sciences, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 830,371 | $498.2K |